Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis

by Xue Song, Kathleen L. Wilson, Jerry Kagan, Sumeet Panjabi
Published 2019-03-01

The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma

by Joanna P MacEwan, Istvan Majer, Jacquelyn W Chou, Sumeet Panjabi
Published 2021-07-01

Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US

by Rafael Fonseca, May Hagiwara, Sumeet Panjabi, Emre Yucel, Jacqueline Buchanan, Thomas Delea
Published 2021-02-01

A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting

by Robert M. Rifkin, Rohan Medhekar, E. Susan Amirian, Kathleen M. Aguilar, Thomas Wilson, Marley Boyd, Khalid Mezzi, Sumeet Panjabi
Published 2019-01-01